DexCom Price To Sales vs. Shares Outstanding

D1EX34 Stock  BRL 9.33  0.32  3.32%   
Taking into consideration DexCom's profitability measurements, DexCom Inc may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess DexCom's ability to earn profits and add value for shareholders.
For DexCom profitability analysis, we use financial ratios and fundamental drivers that measure the ability of DexCom to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well DexCom Inc utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between DexCom's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of DexCom Inc over time as well as its relative position and ranking within its peers.
  
Check out Investing Opportunities.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

DexCom Inc Shares Outstanding vs. Price To Sales Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining DexCom's current stock value. Our valuation model uses many indicators to compare DexCom value to that of its competitors to determine the firm's financial worth.
DexCom Inc is rated below average in price to sales category among its peers. It also is rated below average in shares outstanding category among its peers creating about  37,414,966  of Shares Outstanding per Price To Sales. Comparative valuation analysis is a catch-all model that can be used if you cannot value DexCom by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for DexCom's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

DexCom Shares Outstanding vs. Price To Sales

Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

DexCom

P/S

 = 

MV Per Share

Revenue Per Share

 = 
129.36 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

DexCom

Shares Outstanding

 = 

Public Shares

-

Repurchased

 = 
4.84 B
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.

DexCom Shares Outstanding Comparison

DexCom is rated below average in shares outstanding category among its peers.

DexCom Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in DexCom, profitability is also one of the essential criteria for including it into their portfolios because, without profit, DexCom will eventually generate negative long term returns. The profitability progress is the general direction of DexCom's change in net profit over the period of time. It can combine multiple indicators of DexCom, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California. DEXCOM INC operates under Diagnostics Research classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 5500 people.

DexCom Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on DexCom. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of DexCom position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the DexCom's important profitability drivers and their relationship over time.

Use DexCom in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DexCom position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DexCom will appreciate offsetting losses from the drop in the long position's value.

DexCom Pair Trading

DexCom Inc Pair Trading Analysis

The ability to find closely correlated positions to DexCom could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DexCom when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DexCom - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DexCom Inc to buy it.
The correlation of DexCom is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DexCom moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DexCom Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DexCom can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your DexCom position

In addition to having DexCom in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Target Outcome ETFs Thematic Idea Now

Target Outcome ETFs
Target Outcome ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Target Outcome ETFs theme has 92 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Target Outcome ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Information and Resources on Investing in DexCom Stock

When determining whether DexCom Inc is a strong investment it is important to analyze DexCom's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DexCom's future performance. For an informed investment choice regarding DexCom Stock, refer to the following important reports:
Check out Investing Opportunities.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
To fully project DexCom's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of DexCom Inc at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include DexCom's income statement, its balance sheet, and the statement of cash flows.
Potential DexCom investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although DexCom investors may work on each financial statement separately, they are all related. The changes in DexCom's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on DexCom's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.